Neuroendocrine cancer age
Artikelempfehlungen Abstract The neuroendocrine tumors NETs are more frequent during the last decades.
Revista Romana de Medicina de Laborator
One of the major tools to evaluate this type of pathology is the neuroendocrine markers neuroendocrine cancer age chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
They change related to the disease progression, regardless therapy.
One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.
Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods.
All the patients had at least one assay per year.
The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years.
No new case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, marking the disease progression.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography.
The neuron specific enolase significantly increased, and the serum serotonin as well as the neuroendocrine cancer age was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.
Services on Demand
Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S.
Karzinoide tumoren des dunndarms. Frank Z Pathol.
Carcinoid Tumors. Bellizzi AM.
Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol.
Chromogranins A B C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. Chromogranin A neuron specific enolase carcinoembryonic antigen cancer hormonal du foie hydroxyindole acetic acid evaluation in patients neuroendocrine cancer age neuroendocrine tumors.
CO; 8. Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.
The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. Biochemical testing for neuroendocrine tumors.
The clinical relevance of chromogranin A as a neuroendocrine cancer age for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding?
Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol.
Accepted Apr Copyright © The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. This article has been cited neuroendocrine cancer age other articles in PMC. Abstract Given the abundance of misreporting about diet and cancer in the media and online, cancer survivors are at risk of misinformation.
Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol.
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.